Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 


 

Innovative Health Care Portfolio, Series 1
Ticker Symbol: FMDPUX

40 Holdings (As of Day of Deposit)
Ticker Name Initial
Weight
Price*
Advanced Life Sciences
TECH Bio-Techne Corporation 2.50% $192.85
ILMN Illumina, Inc. 2.46% 284.77
IQV IQVIA Holdings Inc. 2.54% 152.15
RGEN Repligen Corporation 2.51% 88.40
TMO Thermo Fisher Scientific Inc. 2.53% 273.31
ZTS Zoetis Inc. 2.52% 123.68
Electronic Healthcare
HQY HealthEquity, Inc. 2.49% 61.22
PHG Koninklijke Philips N.V. (NY Shares) 2.50% 45.54
TRHC Tabula Rasa HealthCare, Inc. 2.52% 61.78
TDOC Teladoc Health, Inc. 2.50% 56.94
Gene & Cell Therapy
BOLD Audentes Therapeutics, Inc. 2.50% 32.95
BIIB Biogen Inc. 2.53% 227.63
BMRN BioMarin Pharmaceutical Inc. 2.48% 71.73
BLUE bluebird bio, Inc. 2.53% 116.99
BMY Bristol-Myers Squibb Company 2.51% 45.75
CRSP CRISPR Therapeutics AG 2.50% 46.10
EDIT Editas Medicine, Inc. 2.51% 25.36
GILD Gilead Sciences, Inc. 2.48% 62.87
MRNA Moderna, Inc. 2.50% 12.67
SGMO Sangamo Therapeutics, Inc. 2.50% 11.05
VRTX Vertex Pharmaceuticals Incorporated 2.46% 181.12
Oncology
HALO Halozyme Therapeutics, Inc. 2.51% 15.85
MRTX Mirati Therapeutics, Inc. 2.50% 90.12
ZYME Zymeworks Inc. 2.50% 25.00
Rare Disease
ALXN Alexion Pharmaceuticals, Inc. 2.49% 109.04
ALNY Alnylam Pharmaceuticals, Inc. 2.52% 78.37
AMGN Amgen Inc. 2.46% 199.31
FOLD Amicus Therapeutics, Inc. 2.50% 9.99
ICPT Intercept Pharmaceuticals, Inc. 2.51% 64.64
PTCT PTC Therapeutics, Inc. 2.49% 44.34
SRPT Sarepta Therapeutics, Inc. 2.48% 121.97
RARE Ultragenyx Pharmaceutical Inc. 2.49% 56.87
Robotic Surgery
ALGN Align Technology, Inc. 2.48% 174.37
GMED Globus Medical, Inc. 2.50% 48.71
ISRG Intuitive Surgical, Inc. 2.47% 499.87
JNJ Johnson & Johnson 2.50% 130.54
MDT Medtronic Plc 2.51% 101.75
NUVA NuVasive, Inc. 2.49% 63.13
SYK Stryker Corporation 2.53% 215.30
ZBH Zimmer Biomet Holdings, Inc. 2.50% 135.13

* As of the close of business on 8/15/19.
Market values are for reference only and are not indicative of your individual cost basis.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value

Portfolio Summary
Initial Date of Deposit 8/16/2019
Initial Public Offering Price $10.00 per Unit
Portfolio Ending Date 11/17/2020
Cash CUSIP 30298H225
Reinvestment CUSIP 30298H233
Fee Account Cash CUSIP 30298H241
Fee Account Reinvestment CUSIP 30298H258

Sales Charges (based on a $10 public offering price)
Standard Accounts
Transactional Sales Charges: Initial: 0.00%
  Deferred: 1.35%
Creation & Development Fee:   0.50%
Maximum Sales Charge:   1.85%

The deferred sales charge will be deducted in three monthly installments commencing 11/20/19.

When the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price exceeds $10.00 per unit, you will pay an initial sales charge.

Fee/Wrap Accounts
Maximum Sales Charge: 0.50%

The maximum sales charge for investors in fee accounts consists of the creation and development fee. Investors in fee accounts are not assessed any transactional sales charges. Standard accounts sales charges apply to units purchased as an ineligible asset.

The creation and development fee is a charge of $.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the creation and development fee will exceed 0.50%.

In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

You should consider the portfolio's investment objectives, risks, and charges and expenses carefully before investing. Contact your financial advisor or call First Trust Portfolios L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the portfolio. Read it carefully before you invest.

Risk Considerations
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

You should be aware that the portfolio is concentrated in stocks in the health care sector which involves additional risks, including limited diversification. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends.

An investment in a portfolio containing equity securities of foreign issuers is subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers.

An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Although this portfolio terminates in approximately 15 months, the strategy is long-term. Investors should consider their ability to pursue investing in successive portfolios, if available. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cyber security.

 
Fund Cusip Information
30298H225 (Cash)
30298H233 (Reinvest)
30298H241 (Cash-Fee)
30298H258 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page
 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial advisors are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2019 All rights reserved.